These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 35514116)

  • 1. Nonclinical safety assessment of an mRNA Covid-19 vaccine candidate following repeated administrations and biodistribution.
    Broudic K; Laurent S; Perkov V; Simon C; Garinot M; Truchot N; Latour J; Désert P
    J Appl Toxicol; 2024 Mar; 44(3):371-390. PubMed ID: 37723625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational characterization of the mammalian-expressed SARS-CoV-2 recombinant receptor binding domain, a COVID-19 vaccine.
    Moro-Pérez L; Boggiano-Ayo T; Lozada-Chang SL; Fernández-Saiz OL; de la Luz KR; Gómez-Pérez JA
    Biol Res; 2023 May; 56(1):22. PubMed ID: 37150832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models.
    Kaiser FK; Hernandez MG; Krüger N; Englund E; Du W; Mykytyn AZ; Raadsen MP; Lamers MM; Rodrigues Ianiski F; Shamorkina TM; Snijder J; Armando F; Beythien G; Ciurkiewicz M; Schreiner T; Gruber-Dujardin E; Bleyer M; Batura O; Erffmeier L; Hinkel R; Rocha C; Mirolo M; Drabek D; Bosch BJ; Emalfarb M; Valbuena N; Tchelet R; Baumgärtner W; Saloheimo M; Pöhlmann S; Grosveld F; Haagmans BL; Osterhaus ADME
    Nat Commun; 2024 Mar; 15(1):2319. PubMed ID: 38485931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of general toxicity and safety pharmacology of a receptor-binding domain-based COVID-19 subunit vaccine in various animal models.
    Park SJ; Jang MS; Lim KH; Seo JW; Im WJ; Han KH; Kim SE; Jang E; Park D; Kim YB
    Arch Toxicol; 2023 Sep; 97(9):2429-2440. PubMed ID: 37491472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in SARS-CoV-2 receptor-binding domain-based COVID-19 vaccines.
    Guan X; Yang Y; Du L
    Expert Rev Vaccines; 2023; 22(1):422-439. PubMed ID: 37161869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel
    Nechooshtan R; Ehrlich S; Vitikainen M; Makovitzki A; Dor E; Marcus H; Hefetz I; Pitel S; Wiebe M; Huuskonen A; Cherry L; Lupu E; Sapir Y; Holtzman T; Aftalion M; Gur D; Tamir H; Yahalom-Ronen Y; Ramot Y; Kronfeld N; Zarling D; Vallerga A; Tchelet R; Nyska A; Saloheimo M; Emalfarb M; Ophir Y
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19.
    Chen WH; Hotez PJ; Bottazzi ME
    Hum Vaccin Immunother; 2020 Jun; 16(6):1239-1242. PubMed ID: 32298218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and Local Tolerance of a Novel Spike Protein RBD Vaccine Against SARS-CoV-2, Produced Using the C1
    Ramot Y; Kronfeld N; Ophir Y; Ezov N; Friedman S; Saloheimo M; Vitikainen M; Ben-Artzi H; Avigdor A; Tchelet R; Valbuena Crespo N; Emalfarb M; Nyska A
    Toxicol Pathol; 2022 Apr; 50(3):294-307. PubMed ID: 35514116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system
    Gonzalez-Hernandez M; Kaiser FK; Steffen I; Ciurkiewicz M; van Amerongen G; Tchelet R; Emalfarb M; Saloheimo M; Wiebe MG; Vitikainen M; Albulescu IC; Bosch BJ; Baumgärtner W; Haagmans BL; Osterhaus ADME
    Front Immunol; 2023; 14():1204834. PubMed ID: 37359531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice.
    Lazo L; Bequet-Romero M; Lemos G; Musacchio A; Cabrales A; Bruno AJ; Ariel Espinosa L; Saloheimo M; Vitikainen M; Hernández A; Emalfarb M; Tchelet R; Suzarte E; Guillén G
    Vaccine; 2022 Feb; 40(8):1162-1169. PubMed ID: 35078661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.